LIDDS was founded based on an invention that enables a controlled and sustained local release of drugs, later called the NanoZolid technology. The first patent application covering this invention was filed in 2003. The primary focus of the company for the first 15 years was the development of Liproca Depot for the treatment of prostate cancer patients.
LIDDS enters into an R&D agreement with Johnson & Johnson Enterprise Innovation Inc. Extensive management changes and a strategic review are conducted within LIDDS. The phase I clinical study investigating nanodotax in different solid tumors is closed.